{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:17:54Z","timestamp":1790140674649,"version":"4.0.1"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GAVI, the Vaccine Alliance"},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"US Centers for Disease Control and Prevention","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2023,6,10]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Since 2000, the incidence of measles and rubella has declined as measles\u2013rubella (MR) vaccine coverage increased due to intensified routine immunisation (RI) and supplementary immunisation activities (SIAs). The World Health Assembly commissioned a feasibility assessment of eliminating measles and rubella. The objective of this paper is to present the findings of cost-effectiveness analysis (CEA) of ramping up MR vaccination with a goal of eliminating transmission in every country.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used projections of impact of routine and SIAs during 2018\u20132047 for four scenarios of ramping up MR vaccination. These were combined with economic parameters to estimate costs and disability-adjusted life years averted under each scenario. Data from the literature were used for estimating the cost of increasing routine coverage, timing of SIAs and introduction of rubella vaccine in countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The CEA showed that all three scenarios with ramping up coverage above the current trend were more cost-effective in most countries than the 2018 trend for both measles and rubella. When the measles and rubella scenarios were compared with each other, the most cost-effective scenario was likely to be the most accelerated one. Even though this scenario is costlier, it averts more cases and deaths and substantially reduces the cost of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The Intensified Investment scenario is likely the most cost-effective of the vaccination scenarios evaluated for reaching both measles and rubella disease elimination. Some data gaps on costs of increasing coverage were identified and future efforts should focus on filling these gaps.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2022-011526","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:02:32Z","timestamp":1688994152000},"page":"e011526","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries"],"prefix":"10.1136","volume":"8","author":[{"given":"Ann","family":"Levin","sequence":"first","affiliation":[{"name":"Levin & Morgan LLC, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Burgess","sequence":"additional","affiliation":[{"name":"Self-employed, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Shendale","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winthrop","family":"Morgan","sequence":"additional","affiliation":[{"name":"Levin & Morgan LLC, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-5065","authenticated-orcid":false,"given":"Raymond","family":"Cw Hutubessy","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Measles\u2013rubella Eradication Modelling Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"2025073012534827000_8.7.e011526.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2020.100077","article-title":"The economic burden of measles in children under five in Uganda","volume":"6","author":"De Broucker","year":"2020","journal-title":"Vaccine X"},{"key":"2025073012534827000_8.7.e011526.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05880-5","article-title":"The economic burden of measles in children under five in Bangladesh","volume":"20","author":"de Broucker","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"2025073012534827000_8.7.e011526.3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1989917"},{"key":"2025073012534827000_8.7.e011526.4","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000145479.04559.97"},{"key":"2025073012534827000_8.7.e011526.5","doi-asserted-by":"publisher","DOI":"10.3201\/eid2506.180339"},{"key":"2025073012534827000_8.7.e011526.6","unstructured":"World Health Organization . Measles page. n.d. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/measles"},{"key":"2025073012534827000_8.7.e011526.7","unstructured":"World Health Organization . Rubella page. n.d. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rubella"},{"key":"2025073012534827000_8.7.e011526.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6945a6"},{"key":"2025073012534827000_8.7.e011526.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.027"},{"key":"2025073012534827000_8.7.e011526.10","unstructured":"World Health Organization . Meeting of the strategic advisory group of experts on immunization, October 2018 \u2013 conclusions and recommendations. 2018;49:661\u201380."},{"key":"2025073012534827000_8.7.e011526.11","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00335-7"},{"key":"2025073012534827000_8.7.e011526.12","unstructured":"World Bank . Country and lending groups. n.d. Available: http:\/\/databank.worldbank.org\/data\/download\/site-content\/OGHIST.xlsx"},{"key":"2025073012534827000_8.7.e011526.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"key":"2025073012534827000_8.7.e011526.14","unstructured":"World Health Organization . WHO Guide for standardization of economic evaluations of immunization programmes, 2nd edn. Geneva: World Health Organization,"},{"key":"2025073012534827000_8.7.e011526.15","unstructured":"ICAN cost catalogue. n.d. Available: http:\/\/immunizationeconomics.org\/ican-idcc"},{"key":"2025073012534827000_8.7.e011526.16","unstructured":"Agence De Medicine Preventive . Costing and financing analyses of routine immunization and new vaccine introduction in benin. 2014. Available: https:\/\/immunizationeconomics.org\/wp-content\/uploads\/2024\/01\/FINALREPORT_BENIN.pdf"},{"key":"2025073012534827000_8.7.e011526.17","unstructured":"Guthrie T . Costing and financing analyses of routine immunization in Ugandahealth development for Africa. Rivonia, South Africa. 2014. Available: https:\/\/static1.squarespace.com\/static\/556deb8ee4b08a534b8360e7\/t\/5596fa4ae4b07b7dda4dd04d\/1435957834829\/UGANDA+Immunization+Costing+Report+1+December+14+submitted+FINAL+update+15+12+14+errors.pdf"},{"key":"2025073012534827000_8.7.e011526.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.034"},{"key":"2025073012534827000_8.7.e011526.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.12.029"},{"key":"2025073012534827000_8.7.e011526.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.008"},{"key":"2025073012534827000_8.7.e011526.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2015.04.016"},{"key":"2025073012534827000_8.7.e011526.22","unstructured":"UNICEF supply division. n.d. Available: www.unicef.org\/supply\/vaccines-pricing-date"},{"key":"2025073012534827000_8.7.e011526.23","unstructured":"PAHO revolving fund vaccine prices. n.d. Available: https:\/\/www.paho.org\/en\/documents\/paho-revolving-fund-vaccine-prices-2018"},{"key":"2025073012534827000_8.7.e011526.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.030"},{"key":"2025073012534827000_8.7.e011526.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.045"},{"key":"2025073012534827000_8.7.e011526.26","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-17","article-title":"Costs of early detection systems for epidemic malaria in Highland areas of Kenya and Uganda","volume":"8","author":"Mueller","year":"2009","journal-title":"Malar J"},{"key":"2025073012534827000_8.7.e011526.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2410-0","article-title":"Evaluation of the enhanced meningitis surveillance system, Yendi municipality, northern Ghana, 2010-2015","volume":"17","author":"Kaburi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025073012534827000_8.7.e011526.28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-67","article-title":"Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts","volume":"14","year":"2014","journal-title":"BMC Public Health"},{"key":"2025073012534827000_8.7.e011526.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir096"},{"key":"2025073012534827000_8.7.e011526.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00296-7"},{"key":"2025073012534827000_8.7.e011526.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2015.06.018"},{"key":"2025073012534827000_8.7.e011526.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.035"},{"key":"2025073012534827000_8.7.e011526.33","doi-asserted-by":"crossref","unstructured":"McKay MD . Latin Hypercube sampling as a tool in uncertainty analysis of computer models. the 24th conference; Arlington, Virginia, United States.New York, New York, USA, 1992:557\u201364 doi:10.1145\/167293.167637","DOI":"10.1145\/167293.167637"},{"key":"2025073012534827000_8.7.e011526.34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir132"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2022-011526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:54:00Z","timestamp":1753905240000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2022-011526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjgh-2022-011526"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2022-011526","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}